Moxifloxacine Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacine Fresenius Kabi, is a fluoroquinolone presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in adults, including community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and soft‑tissue infections, and intra‑abdominal infections, and is indicated for severe infections requiring hospitalisation.

GNH USA supplies Moxifloxacine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality and regulatory compliance across all markets.

Moxifloxacin is a fluoroquinolone antibiotic used to treat bacterial infections in several organ systems.

- Community‑acquired bacterial pneumonia: achieves bacterial eradication and clinical cure in adult patients. - Acute bacterial sinusitis: reduces symptoms and eliminates the causative pathogens. - Acute exacerbations of chronic bronchitis: improves lung function and shortens disease duration. - Skin and skin structure infections: resolves infection and promotes tissue healing. - Intra‑abdominal infections: clears polymicrobial infection and supports recovery after surgery.

Moxifloxacin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles. - QT interval prolongation: risk of cardiac arrhythmia, monitor ECG. - Severe hypersensitivity reactions: anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis.

When using Moxifloxacine Fresenius Kabi, clinicians should consider several safety measures to minimize risk.

- Renal function: assess and adjust in severe renal impairment. - QT prolongation: monitor ECG in patients with cardiac risk factors. - Allergy: discontinue immediately if hypersensitivity reaction occurs. - Concomitant corticosteroids: avoid or monitor for increased tendon rupture risk. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., quinidine, macrolides, antiarrhythmics): may increase risk of torsades de pointes. - Systemic corticosteroids: combined use raises tendon rupture risk. - Other fluoroquinolones: additive toxicity without added benefit.

Moderate Interactions (Monitor Closely): - Antacids or supplements containing magnesium or aluminum: reduce absorption; separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Theophylline: may increase plasma concentrations; observe for signs of toxicity.